Letter to the Editors
Different studies highlight the importance of augmentative strategies to risperidone as an effective pharmacological approach for treating behavioral symptoms associated with autistic spectrum disorder (ASD). 1 The objective of the present study was to assess the combined clinical effects of different addon pharmacological therapies to risperidone in the management of patients with ASD.
After searching MEDLINE and EMBASE databases, we performed a systematic review following the PRISMA statement guidelines. 2 We also looked for controlled trials by contacting experts and searching the website clinicaltrials.gov. The criteria used to select articles were: 1) English language; 2) randomized, controlled trials;
3) mean and standard deviation values provided; and 4) response and remission rates provided. We excluded controlled trials assessing therapies different from our study objective. We opted to use Hedges' g to measure the effect size as it is appropriate for small sample sizes. The pooled effect size was weighted by the inverse variance method and measured under the random effect model. Heterogeneity was assessed using I 2 index. We further used funnel plots to check for the existence of publication bias.
A total of 6 out of 51 randomized controlled trials met the eligibility criteria (n = 231, mean age = 8.25
years) [3] [4] [5] [6] [7] [8] [9] (Table 1 
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